Search alternatives:
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
16 we » 16 w (Expand Search), 1_ we (Expand Search)
Showing 321 - 340 results of 43,819 for search '(( 16 we decrease ) OR ( 5 ((we decrease) OR (((nn decrease) OR (mean decrease)))) ))', query time: 0.71s Refine Results
  1. 321
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 322
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 323
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 324
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 325
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 326
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 327
    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences.

    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

    Published 2022
    Save to List
    Saved in:
  8. 328
    Distribution of mean seasonal rainfall in the study area.

    Distribution of mean seasonal rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 329
    Distribution of mean monthly rainfall in the study area.

    Distribution of mean monthly rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 330
    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone.

    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone. by Brenda Lyn A. Gavina (15285185)

    Published 2023
    Save to List
    Saved in:
  11. 331
    Descriptive statistics of data presented in Tables 2–5.

    Descriptive statistics of data presented in Tables 2–5. by Héctor Raúl Olivares-Sánchez (13014866)

    Published 2022
    Save to List
    Saved in:
  12. 332
    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression.

    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

    Published 2023
    Save to List
    Saved in:
  13. 333
    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR.

    Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. by Jordan A. Gunning (18143970)

    Published 2024
    Save to List
    Saved in:
  14. 334
    Fig 5 -

    Fig 5 - by Harshita Sharma (4836180)

    Published 2023
    Save to List
    Saved in:
  15. 335
    Descriptive statistics (mean [standard deviation] or % [sample size]) for study variables analyzed in the current study.

    Descriptive statistics (mean [standard deviation] or % [sample size]) for study variables analyzed in the current study. by Angelina R. Sutin (9216456)

    Published 2022
    Save to List
    Saved in:
  16. 336
    Image_5_Decreased Evoked Slow-Activity After tDCS in Disorders of Consciousness.PNG

    Image_5_Decreased Evoked Slow-Activity After tDCS in Disorders of Consciousness.PNG by Armand Mensen (516668)

    Published 2020
    Save to List
    Saved in:
  17. 337
    Mean change in pain severity and interference from baseline to 8 weeks.

    Mean change in pain severity and interference from baseline to 8 weeks. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 338
    Effects of FE and RUD wrist postures on the mean carpal tunnel depth within each quartile.

    Effects of FE and RUD wrist postures on the mean carpal tunnel depth within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  19. 339
    Effects of FE and RUD wrist postures on the mean carpal tunnel width within each quartile.

    Effects of FE and RUD wrist postures on the mean carpal tunnel width within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  20. 340
    Effects of FE and RUD wrist postures on the mean cross-sectional area within each quartile.

    Effects of FE and RUD wrist postures on the mean cross-sectional area within each quartile. by Drew A. Anderson (14197446)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: